Physician profile
Ian M Carr
NPI 1104017847
$5,672.48
in general payments reported to CMS, 2019-2025
23 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $160 · 2021: $301 · 2022: $602 · 2023: $1,818 · 2024: $990 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Honoraria: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.84 |
| Honoraria | $1,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $2,120.46 | 2019-2025 | |
| Alcon Vision LLC | $664.26 | 2019-2025 | Precision 1, Dailies, Precision7 |
| Bausch & Lomb Americas INC. | $553.64 | 2022-2025 | Infuse, Miebo, Biotrue One Day |
| Coopervision INC. | $406.59 | 2019-2025 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $397.07 | 2019-2025 | Cequa, Xelpros |
| Shire North American Group INC | $266.42 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $250.61 | 2019-2025 | Acuvue |
| Eyevance Pharmaceuticals LLC | $169.63 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.92 | 2019-2021 | |
| Oyster Point Pharma, INC. | $132.75 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Horizon Therapeutics Plc | $122.18 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $92.49 | 2019-2023 | |
| Biotissue Holdings INC. | $51.32 | 2022-2023 | |
| Lombart Brothers, INC. | $43.48 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $41.56 | 2024-2025 | Xdemvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $41.04 | 2021-2022 | |
| Harrow Eye, LLC | $26.97 | 2025 | Vevye |
| Allergan, INC. | $26.94 | 2020 | |
| Ani Pharmaceuticals, INC. | $21.80 | 2025 | Purified Cortrophin Gel |
| Thea Pharma INC. | $20.60 | 2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $19.87 | 2019 | |
| Amgen INC. | $19.80 | 2024 | Tepezza |
| Abb Con-Cise Optical Group LLC | $15.08 | 2024 | Contact Lens, Spectacle Lenses |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.